by Phillip B. Maples, PhD, Padmasini Kumar, Yang Yu, Zhaohui Wang, PhD, Chris Jay, PhD, Beena O. Pappen, Donald D. Rao, PhD, Joseph Kuhn, MD, John Nemunaitis, MD, and Neil Senzer, MD
Volume 8, Issue 4 (Winter 2009/2010)
Based on our previously published TAG vaccine design and the TAG vaccine clinical results to date (which demonstrate safety and evidence of efficacy — stabilizing disease plus one confirmed complete response; data submitted elsewhere), we have moved forward with a fundamentally new autologous tumor cell vaccine design incorporating a key technical enhancement through our proprietary bifunctional shRNA technology. The resulting FANG vaccine expresses both recombinant human GM-CSF protein and a furin bifunctional shRNA which blocks the expression of furin protein, and then in turn, significantly reduces the expression of both TGFß1 and TGFß2 in all primary human tumors tested to date…
Citation:
Maples PB, Kumar P, Yu Y, Wang Z, Jay C, Pappen BO, Rao DD, Kuhn J, Nemunaitis J, Senzer N. FANG Vaccine: Autologous Tumor Cell Vaccine Genetically Modified to Express GM-CSF and Block Production of Furin. BioProcess J, 2009; 8(4): 4-14. http://dx.doi.org/10.12665/J84.Maples